Ultra long acting basal insulin - Gan & Lee Pharmaceuticals
Alternative Names: GZR-33Latest Information Update: 26 Aug 2024
At a glance
- Originator Gan&Lee Pharmaceuticals
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetes mellitus
Most Recent Events
- 28 Jun 2024 Phase-II clinical trials in Diabetes mellitus in China (Parenteral) (NCT06558708)
- 21 Jun 2024 Pharmacodynamics and pharmacokinetic data from a preclinical trial in Diabetes mellitus presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)
- 03 Feb 2024 Gan and Lee Pharmaceuticals completes the phase I trial in Diabetes mellitus (In volunteers) in China (SC) (NCT06556641)